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BACKGROUND: We investigated whether elevation in serum cytomegalovirus (CMV) or Epstein–Barr virus (EBV) immunoglobulin G
(IgG) antibody levels precedes the development of breast cancer.
METHODS: A nested case–control study was carried out within the Janus Serum Bank cohort. Two serum samples, one taken at least
4 years before diagnosis (sample 2) and an earlier sample (sample 1) from 399 women with invasive breast cancer and from
399 controls, matched for date of blood samples and age were tested for CMV and EBV IgG antibodies. Odds ratios (ORs) with
95% confidence intervals (CIs) for CMV and EBV seroconversion between the samples and unit changes in IgG optical density (OD)
examined as a continuous variable were calculated using conditional logistic regression.
RESULTS: Eleven cases and three controls seroconverted for CMV IgG between the first and second blood samples, with an
adjusted OR for CMV IgG seroconversion of 4.0 (95% CI¼1.1–14.4). The risk of breast cancer, adjusted for parity, increased
per unit difference in CMV OD between samples (OR¼1.7, 95% CI¼1.1–2.5). In an analysis restricted to parous cases
and age-matched parous controls, the OR for CMV seroconversion for IgG between the two samples, adjusted for parity and
age at first birth, was 9.7 (95% CI¼1.2–77.3). The EBV seroconversion or change in EBV OD was not associated with risk of
breast cancer.
CONCLUSION: Our hypothesis that elevation in serum CMV IgG antibody levels precedes the development of breast cancer in some
women is supported by the results of this study. Changes in EBV IgG antibody are not associated with risk of breast cancer.
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There are major geographical differences in the age-standardised
incidence of breast cancer (Ferlay et al, 2004) that cannot be
entirely explained by variations in known risk factors between
countries. Although differences in reproductive factors among
populations are important, a similar geographical pattern for
breast cancer in men has been found (Thomas, 1993).
Mouse mammary tumour-like viruses and Epstein–Barr virus
(EBV) have been suggested to cause breast cancer, but the evidence
that either is associated with breast cancer has been inconsistent
(Xue et al, 2003; Glaser et al, 2004; Mant and Cason, 2004;
Szabo et al, 2005). Recently, cytomegalovirus (CMV) has been
linked to the development of inflammatory diseases and cancer
(So ¨derberg-Naucler, 2006).
It has been hypothesised that breast cancer can be caused by late
exposure to a common virus (Richardson, 1997). Breast cancer
incidence is frequently higher in countries where exposure to
CMV may occur late than in countries where almost everyone is
exposed in childhood. A strong negative inter-country correlation
(Pearson’s correlation coefficient  0.79, Po0.0001) was found
between breast cancer incidence and the percentage of adults who
are CMV seropositive (Richardson, 1997).
Delayed exposure to EBV (or CMV), measured by illness from
infectious mononucleosis, has been suggested to increase risk
of breast cancer (Yasui et al, 2001), but recall bias may have
influenced the results.
In an Australian case–control study, cases and controls did not
differ in seropositivity for CMV or EBV (Richardson et al, 2004).
However, in seropositive women, mean immunoglobulin G (IgG)
values were higher in cases than controls for CMV (1.20 vs 0.98
optical density (OD), P¼0.005), but not for EBV (2.65 vs 2.57 OD,
P¼0.5). The adjusted odds ratios (ORs) per OD unit were 1.46
(95% confidence interval (CI)¼1.06–2.03) for CMV IgG and 1.11
(95% CI¼0.93–1.33) for EBV IgG. We hypothesised that the
higher mean IgG levels found in women with breast cancer could
be the result of more recent infection with CMV, and may indicate
that late exposure to CMV (in adulthood rather than childhood) is
a risk factor for breast cancer. Limitations of this work were that it
was retrospective, with blood samples collected after the diagnosis
of breast cancer, and only women aged o40 years were studied.
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To investigate whether CMV IgG levels were increased before
the diagnosis of breast cancer, a case–control study nested in
the cohort of female donors to the Janus Serum Bank in Norway
was undertaken. The Janus project was started in 1973 to collect
and store blood samples from healthy people for later scientific
use. Participants were recruited from several counties in Norway
during routine health examinations or in conjunction with
screening for risk factors of cardiovascular diseases. The
participation rate was 85% during 1974 to 1978 and 75% during
1986 to 1991. Samples were also collected from blood donors from
the Red Cross Blood Donor Centre in Oslo. The serum bank
contains samples from approximately 333000 people (151000
women) and 10% are blood donors. The sera have been stored at
 251C (Jellum et al, 1993, 1995).
The stored blood samples from cases and controls were tested
for CMV and EBV IgG antibodies. The CMV and EBV antibody
levels in stored blood remain stable despite prolonged storage
(Jellum et al, 1993; Pappin et al, 1995; Levin et al, 2003). The study
was approved by the Regional Ethics Committee of Southern
Norway and Data Inspectorate, Norway.
Selection of cases and controls
Cases were randomly selected from women in the Janus Serum
Bank cohort with invasive breast cancer who had been identified
by linkage to the Norwegian Cancer Registry until 400 cases were
attained. Women were eligible to be cases if they were aged
20 years and over at diagnosis, with a blood sample taken 4 or more
years before the diagnosis of breast cancer (the index sample), and
a blood sample at least 12 months earlier than the index sample.
Eligible controls were women from the cohort who were alive and
free of cancer (other than squamous or basal cell carcinoma of the
skin) at the time that the case was diagnosed. They were frequency
matched to the cases by 5-year age group and had a blood sample
taken within ±2 months of the index sample of the case. From
these eligible controls, women with at least one earlier sample were
randomly selected. These controls were individually matched to
cases by duration of sample storage (±2 months) of the earlier
sample. Where it was not possible to find a control in which the
earlier sample could be matched for duration of storage, an eligible
control with the closest available early sample was randomly
selected. The two samples for each case and individually matched
control had to be separated in time by at least 12 months to allow
adequate time for IgG levels to change between the samples, as
CMV and EBV IgG titres rise initially after infection and then
gradually decline, with residual antibody detectable for several
years (IARC Working Group on the Evaluation of Carcinogenic
Risks to Humans, 1997; Mendez et al, 1999). Table 1 shows the
selection criteria for cases and controls.
Sample size calculations
On the basis of our earlier results (Richardson et al, 2004), samples
from 400 cases and 400 controls were predicted to provide, for the
assessment of CMV and EBV IgG levels, at least 80% power to
detect a difference of 0.15 units of OD in mean CMV IgG levels
between cases and controls (a difference of 21.4% of the s.d.), with
a¼0.05. As we also wished to examine changes in CMV IgG and
EBV IgG levels over time in cases and controls, two samples for
each case and each control were tested. We had no estimates of the
magnitude of changes in CMV or EBV IgG over time or the rate of
seroconversion, so they were not used to estimate the sample size
or statistical power of the study, however, the CIs indicate the
precision of the ORs obtained. In total, 1600 samples were tested;
800 from the cases (two samples from each of the 400 cases) and
800 from the controls (two samples from each of the 400 controls).
Conditional logistic regression using COXREG in SPSS (SPSS
Inc., 2007) was used to estimate ORs for factors associated with
the risk of breast cancer. The date of diagnosis was taken as the
reference date for each case and their matched control for the
calculation of age. Parity and age at first child were obtained from
the information recorded when the second blood sample was
drawn and were included in the analysis. Odds ratios, with 95%
CIs, for CMV and EBV unit changes in IgG OD, and differences in
values between samples, examined as continuous variables and
adjusted for parity, as well as CMV and EBV seroconversion, were
calculated. For analysis in parous women, adjustment for parity
and age at first child was also undertaken. Analyses for women
diagnosed before 1998 and from 1998 onwards and their matched
controls were undertaken to assess whether the introduction of the
national breast screening programme in Norway in 1998
influenced the results. For 572 subjects, height and weight were
measured as part of the assessment of cardiovascular risk factors
within the cohort resulting in 277 case–control pairs with body
mass index (BMI) measurements for analysis (69% of all case–
control pairs). Body mass index was categorised into four groups:
o22, 22.1–24, 24.1–26 and 426. Use of hormone replacement
therapy was not recorded.
Serological tests
The serological tests were carried out in Norway at the Institute of
Microbiology, Rikshospitalet, Oslo, Norway. Each blood sample
was tested using standard enzyme immunoassays for CMV IgG
and EBV viral capsid antigen IgG. The serum specimens were
organised as 32 batches, each comprising 12 sets. Two specimens
from a case and two specimens from the corresponding control
comprised one set. The specimens within a batch were then mixed.
Specimens from the same set were in the same batch, but not
necessarily next to each other.
The CMV IgG and EBV-VCA antibody internal control sera were
placed in wells in the first row and last row of each test plate. If the
OD of these two wells on the test plate differed by 420%, the
results were rejected and the sera reanalysed. In addition, an
internal laboratory control was analysed on each plate to control
inter-assay variations.
The CMV IgG antibodies were assessed by Enzygnost Anti-
CMV/IgG test kit, Dade Behring, Marburg, Germany. The OD
cutoff value was 0.200. A reference serum provided with the kit was
used as a correction factor to standardise the OD value between
test plates. The EBV-VCA IgG antibodies were assessed by Novitec
EBV-VCA IgG test kit, Hiss Diagnostics, Freiburg, Germany. The
OD cutoff value for this test was also 0.200.
RESULTS
Cases of breast cancer were diagnosed between February 1982 and
December 2003, with 53% of cases diagnosed from 1998 onwards.
Table 1 Eligibility of cases and controls
Cases Controls
Women aged 20 years and over
at diagnosis with invasive breast
cancer (identified by linkage to the
Norwegian Cancer Registry)
Women alive without cancer (other than
basal or squamous cell skin cancer) at the
time the case was diagnosed, aged in the
same 5-year age group as the case
Available stored blood sample taken
at least 4 years before the diagnosis
of breast cancer (the ‘index sample’)
Available stored blood sample taken
within ±2 months of the case’s index
sample
Earliest available stored blood sample
(taken at least 1 year earlier than
the index sample described above)
Available early sample (preferably
taken within ±2 months of the case’s
sample, but otherwise the closest early
sample taken at least 1 year earlier
than the sample described above)
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yOne woman with DCIS only and her matched control were
excluded, leaving 399 case–control pairs for analysis. The
distribution of age and parity in cases and controls is shown in
Table 2. The age distribution of cases and controls was similar due
to matching on age. Parity was significantly different between cases
and controls (w
2¼12.83, 5 df, P¼0.025) with similar proportions
of nulliparous women, but fewer women with four or more live
births among cases.
For the CMV IgG antibodies, the positive control provided with
the kit had a mean OD value of 0.825±0.110 and the internal
laboratory standard had a mean OD value of 0.235±0.052. For the
EBV-VCA IgG antibodies, the positive control provided with the
kit had a mean OD value of 2.610±0.230 and the internal
laboratory standard had a mean OD value of 0.900±0.13.
The average time between serum samples was 8.5 years (range
1–17 years). Of the cases, 314 (78.7%) were seropositive for CMV
at their second serum sample compared with 329 (82.5%) of the
controls. Eleven cases and three of the controls seroconverted for
CMV IgG between the first and second samples (P¼0.03). This
effect was largely confined to parous women (10 cases and 2
controls). The mean CMV IgG for cases for sample 1 was 1.09 OD
(s.d.¼0.77) and the mean CMV IgG for controls was 1.18 OD
(s.d.¼0.71). The mean CMV IgG for cases for sample 2 was 1.19
OD (s.d.¼0.79) and the mean CMV IgG for controls was 1.22 OD
(s.d.¼0.72). No significant differences in CMV IgG, with
adjustment for parity, were found between cases and controls for
sample 1 or 2 (ORs 0.84, 95% CI¼0.69–1.03 and 0.95, 95%
CI¼0.78–1.15, respectively).
The mean EBV IgG for cases for sample 1 was 2.08 OD
(s.d.¼0.80) and the mean EBV IgG for controls was 2.04 OD
(s.d.¼0.73). The mean EBV IgG for cases for sample 2 was 2.19
OD (s.d.¼0.82) and the mean EBV IgG for controls was 2.17 OD
(s.d.¼0.80). With adjustment for parity, no significant differences
in EBV IgG were found between cases and controls for sample 1
or 2 (ORs 1.04, 95% CI¼0.86–1.27 and 1.03, 95% CI¼0.85–1.23,
respectively). For EBV, 386 (96.7%) of cases were seropositive
when the second sample was taken compared with 384 (96.2%)
of the controls. Two cases and three controls seroconverted for
EBV IgG between the first and second samples (Table 3).
The CMV IgG levels did not appear to be affected by the
duration of storage of the serum samples and no significant
correlations between CMV IgG or EBV IgG level and duration of
storage were found. There was no difference in the overall
distribution of CMV IgG and EBV IgG levels in cases compared
with controls.
Table 4 shows the risk of breast cancer by parity, age at first
child, BMI and seroconversion for CMV and EBV. There were 343
cases and 344 controls with at least one birth. Among the 301
case–control pairs who were both parous, there was no statistically
significant difference in age at first birth (w
2¼8.11, 4 df, P¼0.09).
Although a significantly increased risk of breast cancer was
observed for parous women whose first birth occurred at age
28 years or older, no increased risk with increasing age at first
birth with adjustment for parity was observed (OR¼1.02, 95%
CI¼0.98–1.06). Nulliparity did not confer reduced risk (OR¼1.0,
95% CI¼0.6–1.5). The risk of breast cancer was significantly
lower for women with five or more children compared with
nulliparous women (OR¼0.3, 95% CI¼0.2–0.7), with or without
adjustment for age at first birth or CMV IgG seroconversion, and
was similar with additional adjustment for BMI for the 277 case–
control pairs for whom it was possible. In parous women, with
adjustment for age at first birth, the risk of breast cancer decreased
with increasing parity with an OR of 0.8 (95% CI¼0.7–0.9) per
additional child after the first and was not appreciably changed
with additional adjustment for age at first birth.
Seroconversion for CMV IgG between the first and second
samples occurred for 11 cases and 3 controls, producing an
unadjusted OR of 3.7 (95% CI¼1.0–13.1). When adjusted for
parity, the OR for CMV IgG seroconversion was 4.0 (95%
CI¼1.1–14.4). This was unaltered by adjustment for the length
of time between tests, and was similar when restricted to case–
control pairs for diagnoses before 1998 or 1998 onwards, OR¼4.3
(95% CI¼0.5–38.4) and OR¼3.9 (95% CI¼0.8–18.9), respec-
tively. When only case–control pairs who were parous were
included in the analysis (10 cases and 2 controls seroconverted),
the unadjusted OR for CMV IgG seroconversion was 9.0 (95%
CI¼1.1–71.0), and this was increased slightly to 9.7 (95%
CI¼1.2–77.3) when adjusted for parity and age at first birth.
The estimate was not altered significantly when the analysis was
restricted to women over 50 years of age at diagnosis or reference
date; OR¼9.9 (95% CI¼1.2–78.8).
When the analysis was restricted to the subgroup for whom
BMI was measured, the OR for the association between CMV
Table 2 Characteristics of cases and controls
Characteristic Number of cases (%) Number of controls (%)
Age (years)
20–44 12 (3.0%) 11 (2.8%)
45–49 16 (4.0%) 19 (4.8%)
50–54 52 (13.0%) 58 (14.5%)
55–59 87 (21.8%) 79 (19.8%)
60–64 91 (22.8%) 100 (25.1%)
65–69 93 (23.3%) 83 (20.8%)
70+ 48 (12.0%) 49 (12.3%)
Number of children
None 56 (14.0%) 55 (13.8%)
1 55 (13.8%) 45 (11.3%)
2 132 (33.1%) 124 (31.1%)
3 103 (25.8%) 92 (23.1%)
4 39 (9.8%) 46 (11.5%)
5+ 14 (3.5%) 37 (9.3%)
Age at first child (for parous women only) (years)
a
0–20 73 (21.3%) 78 (22.7%)
21–22 72 (21.0%) 64 (18.6%)
23–24 55 (16.0%) 73 (21.2%)
25–27 68 (19.8%) 73 (21.1%)
28+ 75 (21.9%) 56 (16.3%)
BMI
b
p22 88 (30.4%) 82 (29.0%)
21.1–24 70 (24.2%) 64 (22.6%)
24.1–26 49 (17.0%) 59 (20.8%)
426 82 (28.4%) 78 (27.6%)
Abbreviation: BMI¼body mass index.
aRestricted to 343 cases and 344 controls
with at least one live birth.
bRestricted to 289 cases and 283 controls with
measurements of BMI.
Table 3 CMV and EBV IgG results for cases and controls
Cases sample 2 Control sample 2
Sample 1 Negative Positive Negative Positive
CMV
Negative 79 11 65 3
Positive 6 303 5 326
EBV
Negative 5 2 5 3
Positive 8 384 10 381
Abbreviations: CMV¼cytomegalovirus; EBV¼Epstein–Barr virus; IgG¼immuno-
globulin G.
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yseroconversion and breast cancer with adjustment for parity was
3.7 (95% CI¼0.7–18.5) and 3.7 (95% CI¼0.7–18.4) when
adjusted for parity and BMI. No trend in the ORs over the four
categories of BMI, with adjustment for parity, was observed
(OR¼0.99, 95% CI¼0.86–1.15). When restricted to parous
women in this subgroup, the OR for CMV seroconversion was
7.6 (95% CI¼0.9–64) and was unchanged with additional
adjustment for age at first birth.
Changes in CMV serology from positive to negative, or staying
positive or staying negative, between samples were not associated
with risk of breast cancer. Only 2 cases and 3 controls
seroconverted for EBV IgG between the two samples.
The crude OR per unit of difference in CMV OD between
samples was 1.6 (95% CI¼1.0–2.3), and the crude OR per unit
difference in EBV OD between samples was 0.9 (95% CI¼0.7–1.3).
Table 5 gives ORs for seroconversion and unit changes in IgG
values between samples, adjusted for parity and, for parous
women, with additional adjustment for age at first birth. The OR
per unit difference in CMV OD between samples, adjusted for
parity, was 1.7 (95% CI¼1.1–2.5), which was reduced to 1.6 (95%
CI¼1.0–2.5) when those that seroconverted for CMV IgG were
excluded. The OR per unit difference in EBV OD between samples,
adjusted for parity, was 1.0 (95% CI¼0.7–1.3). In parous women,
the ORs per unit difference in CMV OD and EBV OD, adjusted for
parity and age at first child, were 2.0 (95% CI¼1.2–3.4) and 1.0
(95% CI¼0.7–1.4), respectively.
DISCUSSION
Our hypothesis that elevation in serum CMV or EBV IgG antibody
levels precedes the development of breast cancer in some women
is supported by the results of this study. Seroconversion of
CMV IgG and increasing IgG levels between the samples were
both associated with an increased risk of breast cancer among
parous women.
The Janus serum bank cohort was ideal for this study because
it meant that blood, which was collected years before the diagnosis
of breast cancer, could be tested, so CMV and EBV IgG levels
for cases are unlikely to have been affected by breast cancer and
were not affected by treatment. Exposure to CMV and EBV was
determined objectively using standard enzyme immunoassays for
CMV IgG and EBV viral capsid antigen IgG, and laboratory staff
were blinded to the case or control status of the samples, so these
results are not vulnerable to recall bias or observer bias. The
similar risk for case–control pairs before and after 1998, the year
the Norwegian Breast Cancer Screening Programme began,
suggests that the results were not affected by detection bias
associated with screening.
Adjustment for the length of time between samples did not alter
the results obtained and suggests that recent seroconversion rather
than the duration of seropositivity may be the more important
determinant of risk of breast cancer. Whether CMV remains in
breast tissue after infection in human beings is not known.
Increased CMV IgG levels may occur from recrudescence of latent
infection or re-exposure to CMV without clinical infection.
Increasing risk of breast cancer with increasing CMV OD might
also occur if a significant risk factor for breast cancer was closely
associated with recurrent CMV exposure.
Day care workers and mothers are at increased risk of acquiring
CMV from children they care for (Bright and Calabro, 1999;
Joseph et al, 2005; Noyola et al, 2005), and this combined with the
recognised increased risk of breast cancer within 10 years of a
full-term birth (Lambe et al, 1994) might explain an association
in parous women. However, when we restricted our analysis to
women who were 50 or more years of age at diagnosis or reference
date in the controls, the strong effect of recent adult CMV infection
in parous women remained, so this is an unlikely explanation of
our results. The specificity of the association (for CMV, but not for
EBV) supports a causal association between adult CMV infection
and breast cancer in some parous women because if the results
were due to bias or confounding an association between breast
cancer and both CMV and EBV infection would be more likely
than either by itself. Although the results for the women with
Table 4 Unadjusted odds ratios for breast cancer by parity, age at first







breast cancer (95% CI)
Nulliparity
No 343 344 1.0
Yes 56 55 1.0 (0.6–1.5)
Number of children
None 56 55 1.0
1 55 45 1.1 (0.7–2.0)
2 132 124 1.1 (0.7–1.7)
3 103 92 1.0 (0.6–1.7)
4 39 46 0.8 (0.4–1.5)
5+ 14 37 0.3 (0.2–0.7)
Age at first child (for parous women only) (years)
a
0–20 63 72 1.0
21–22 68 57 1.4 (0.9–2.4)
23–24 47 66 0.9 (0.5–1.5)
25–27 59 61 1.2 (0.7–2.0)
28+ 64 45 1.8 (1.0–3.3)
BMI
b
p22 83 81 1.0
21.1–24 67 63 1.1 (0.6–1.7)
24.1–26 46 57 0.8 (0.4–1.3)
426 81 76 1.0 (0.6–1.6)
Seroconversion for CMV IgG between samples
No 388 396 1.0
Yes 11 3 3.7 (1.0–13.0)
Seroconversion for CMV IgG between samples in parous women
a
No 333 342 1.0
Yes 10 2 9.0 (1.1–71.0)
Seroconversion for EBV IgG between samples
No 397 396 1.0
Yes 2 3 0.7 (0.1–4.0)
Abbreviations: BMI¼body mass index; CI¼confidence interval; CMV¼cyto-
megalovirus; EBV¼Epstein–Barr virus; IgG¼immunoglobulin G.
aRestricted to
301 cases and 301-matched controls with at least one live birth.
bRestricted to
277 cases and 277-matched controls with BMI available.
Table 5 Adjusted
a odds ratios (95% confidence intervals) for CMV and
EBV seroconversion and unit changes in IgG OD
All women Parous women
Odds ratio 95% CI Odds ratio 95% CI
CMV IgG seroconversion 4.0 1.1–14.4 9.7 1.2–77.3
EBV IgG seroconversion 0.7 0.1–4.0 0.6 0.1–6.8
Unit change in CMV OD 1.7 1.1–2.5 2.0 1.2–3.4
Unit change in EBV OD 1.0 0.7–1.3 1.0 0.7–1.4
Abbreviations: CI¼confidence interval; CMV¼cytomegalovirus; EBV¼Epstein–
Barr virus; IgG¼immunoglobulin G; OD¼optical density.
aResults for all women are
adjusted for number of births; results for 301 parous cases and their 301-matched
parous controls are adjusted for number of births and age at birth of first child.
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ymeasurements of BMI suggest that BMI is not likely to be a
confounder of the associations found between changes in CMV IgG
and breast cancer, other potential confounders, such as the use of
hormone replacement therapy or alcohol consumption, were not
able to be included in the analysis. Further investigation of a
possible function of CMV infection in the presentation of breast
cancer is needed.
The risk of adult CMV infection might be expected to increase
with increasing parity, but increasing parity is associated with a
reducing risk of breast cancer. However, if the prevalence of pre-
invasive disease increased with age and exposure to CMV only
promoted the progression of pre-invasive disease, then infection
from young children after an early age of first full-term birth or
increasing parity would provide some immunity against infection
at an older age, after the onset of pre-invasive disease, and thus
reduce the risk of breast cancer. Then both early age of first birth
and increasing parity would, as has been observed, reduce the
lifetime risk of breast cancer. Moreover, the increased risk of
breast cancer observed within 10 years of first full-term birth
(Lambe et al, 1994) could be mediated through an increased
chance of exposure to CMV after first full-term birth. However,
this hypothesis does not explain the lack of an increased risk of
breast cancer in the 10-year period after first full-term birth for
women whose first full-term birth occurs when 35 or more years of
age (Lambe et al, 1994). The observed increase in risk of breast
cancer in parous women with CMV IgG seroconversion between
samples was present for women diagnosed at 50 or more years of
age, suggesting that CMV infection after 35 years of age may also
increase risk of breast cancer. The increased risk observed was
present for few women in this study, suggesting that CMV
infection may only be involved in the development of a minority of
breast cancers.
Studies involving the long-term follow-up of women who have
been, and not been, infected with CMV are required to verify the
findings of this study. A greater time period between blood
samples would be expected to increase the proportion of women
for whom CMV IgG seroconversion occurs and provide more
definitive examination of the association with breast cancer and
whether risk increases with increasing age of adult CMV infection.
Assessment of whether the increased risk of breast cancer in the
10-year period after first full-term birth varies by occurrence of
CMV infection during the period is also needed.
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